Do investors' personalities predict market winners? Experimental setting and machine learning analysis.

This study uses experiments and surveys from 146 participants who participated in equity trading to explore the predictive power of the Big-five personality traits, social behaviours, along with self-attribution and demographic characteristics on trading performance. Interestingly, we found that investors who are more open and neurotic gain higher returns compared to the market benchmark. We also found that other social traits are associated with the effectiveness of stock trading, such as awareness of social and ethical virtues (fairness and politeness). Moreover, instead of using separate characteristics, this study employs machine learning to cluster these personal features to understand the interconnection between socioeconomic determinants and financial decisions. This study contributes new evidence to the existing literature that personalities could explain trading performance.

Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain.

BACKGROUND: Sublingual (s.l.) administration of soluble protein antigens, inactivated viruses, or virus-like particles has been shown to induce broad immune responses in mucosal and extra-mucosal tissues. Recombinant replication-defective adenovirus vectors (rADVs) infect mucosa surface and therefore can serve as a mucosal antigen delivery vehicle. In this study we examined whether s.l. immunization with rADV encoding spike protein (S) (rADV-S) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) induces protective immunity against SARS-CoV and could serve as a safe mucosal route for delivery of rADV. RESULTS: Here, we show that s.l. administration of rADV-S induced serum SARS-CoV neutralizing and airway IgA antibodies in mice. These antibody responses are comparable to those induced by intranasal (i.n.) administration. In addition, s.l. immunization induced antigen-specific CD8+ T cell responses in the lungs that are superior to those induced by intramuscular immunization. Importantly, unlike i.n. administration, s.l. immunization with rADV did not redirect the rADV vector to the olfactory bulb. CONCLUSION: Our study indicates that s.l. immunization with rADV-S is safe and effective in induction of a broad spectrum of immune responses and presumably protection against infection with SARS-CoV.

Drivers of medical spending behaviour amid the COVID-19 pandemic: Heuristic or systematic.

BACKGROUND: The COVID-19 pandemic has been creating unprecedented chaos and it could forever alter the way people live and work. Experiencing multiple waves of pandemic attacks could make people evolve their perceived risks about the health crisis, change their healthcare behaviours and medical spending to deal with the changing threats over time. OBJECTIVES: Even though there has been a great dealt of research on personal healthcare behaviours during the COVID-19 pandemic, the individual decision on medical spending has not been well explored. This study uses the health belief model and heuristic-systematic information processing theory to study the key drivers of medical spending behaviour as the COVID-19 pandemic evolved in Vietnam. METHODS: Two surveys were conducted during the first (April 2020) and second waves (August 2020) of the COVID-19 pandemic resulted in a sample size of 1037 cases. The partial least square structural equation modeling (PLS-SEM) technique was employed to explore the structural relationships between health-seeking behaviours, pandemic perceived risks, panic buying, and demographic factors and how these sets of factors drive medical spending behaviours over time. RESULTS: Comparing the two pandemic waves, this study finds significant distinctions in how people evaluate the risks of the pandemic and process information to make decisions about their medical spending. People were primarily influenced by the heuristic processes of panic buying patterns (ß = 0.313, p < 0.001) and the health-related established habits in the first wave. Only in the second wave of the pandemic, the impact of the COVID-19 pandemic perceived risk has been recognized as a significant factor on medical spending via the comparison between perceived risks of the first and second pandemic waves (ß = 0.262, p < 0.001). CONCLUSIONS: This study explores how individuals formulate their spending decisions in extreme conditions and provide valuable insights to help governments and institutions plan their policies to combat the COVID-19 pandemic more effectively.

The race Against Time to Save Human Lives During the COVID-19 With Vaccines: Global Evidence.

Voluminous vaccine campaigns have been used globally, since the COVID-19 pandemic has brought devastating mortality and destructively unprecedented consequences to different aspects of economies. This study aimed to identify how the numbers of new deaths and new cases per million changed after half of the population had been vaccinated. This paper used actual pandemic consequence variables (death and infected rates) together with vaccination uptake rates from 127 countries to shed new light on the efficacy of COVID-19 vaccines. The 50% uptake rate was chosen as the threshold to estimate the real benefits of vaccination campaigns for reducing COVID-19 infection and death cases using the difference-in-differences (DiD) imputation estimator. In addition, a number of control variables, such as government interventions and people's mobility patterns during the pandemic, were also included in the study. The number of new deaths per million significantly decreased after half of the population was vaccinated, but the number of new cases did not change significantly. We found that the effects were more pronounced in Europe and North America than in other continents. Our results remain robust after using other proxies and testing the sensitivity of the vaccinated proportion. We show the causal evidence of significantly lower death rates in countries where half of the population is vaccinated globally. This paper expresses the importance of vaccine campaigns in saving human lives during the COVID-19 pandemic, and its results can be used to communicate the benefits of vaccines and to fight vaccine hesitancy.

Financial performances, entrepreneurial factors and coping strategy to survive in the COVID-19 pandemic: case of Vietnam.

Vietnam has been one of a few countries that successfully contained the COVID-19 pandemic. However, aggressive measurements against the pandemic were at the expense of economic activities and companies' financial performances. This cross-sectional study uses a survey of 672 companies in Vietnam and the logistic regression model to explore companies' coping strategy choices based on their degree of financial distress, companies' profiles, entrepreneurial factors, and the interactions between them. The results suggest that companies predominantly selected cost-cutting strategies to deal with the economic shutdown. However, the interactions between financial and entrepreneurial factors could significantly increase the likelihood of selecting growth-focused strategies. Besides, when facing a global pandemic such as COVID-19, managers' perceptions about the spillover effects of global risks were much more impactful than local risks on companies' coping strategy selections. This paper can help to inform managers to better deal with the aftermath of the COVID-19 outbreak.

Baculovirus Displaying Hemagglutinin Elicits Broad Cross-Protection against Influenza in Mice.

The widespread influenza virus infection further emphasizes the need for novel vaccine strategies that effectively reduce the impact of epidemic as well as pandemic influenza. Conventional influenza vaccines generally induce virus neutralizing antibody responses which are specific for a few antigenically related strains within the same subtype. However, antibodies directed against the conserved stalk domain of HA could neutralize multiple subtypes of influenza virus and thus provide broad-spectrum protection. In this study, we designed and constructed a recombinant baculovirus-based vaccine, rBac-HA virus, that expresses full-length HA of pandemic H1N1 influenza virus (A/California/04/09) on the viral envelope. We demonstrated that repeated intranasal immunizations with rBac-HA virus induced HA stalk-specific antibody responses and protective immunity against homologous as well as heterosubtypic virus challenge. The adoptive transfer experiment shows that the cross-protection is conferred by the immune sera which contain HA stalk-specific antibodies. These results warrant further development of rBac-HA virus as a broad-protective vaccine against influenza. The vaccine induced protection against infection with the same subtype as well as different subtype, promising a potential universal vaccine for broad protection against different subtypes to control influenza outbreaks including pandemic.

The Yin-Yang arms of vaccines: disease-fighting power versus tissue-destructive inflammation.

The disease-fighting power of vaccines has defeated many pathogens and has been credited with global reduction of mortality and morbidity. However, most vaccine developments focus on the enhancement of effector responses with systemic inflammation and the consequences overlooked. Recent evidence shows that systemic inflammatory phenotypes, acute or chronic, are both detrimental and should be avoided if possible. Since noninvasive vaccination by painless delivery of nasal vaccines and skin patch vaccines could elicit potent protective immunity without inducing systemic inflammation, it can be predicted that vaccinology will increasingly see the abandonment of the 'needle-injection' paradigm for vaccine development. The findings that specific viral particles could rapidly remodel the tissue environment postinfection in favor of some pathogens with the capacity to suppress others illustrate the pressing need for a deeper understanding of the underlying mechanisms in order to unlock the full potential of immunological intervention.

Sublingual administration of bacteria-expressed influenza virus hemagglutinin 1 (HA1) induces protection against infection with 2009 pandemic H1N1 influenza virus.

Influenza viruses are respiratory pathogens that continue to pose a significantly high risk of morbidity and mortality of humans worldwide. Vaccination is one of the most effective strategies for minimizing damages by influenza outbreaks. In addition, rapid development and production of efficient vaccine with convenient administration is required in case of influenza pandemic. In this study, we generated recombinant influenza virus hemagglutinin protein 1 (sHA1) of 2009 pandemic influenza virus as a vaccine candidate using a well-established bacterial expression system and administered it into mice via sublingual (s.l.) route. We found that s.l. immunization with the recombinant sHA1 plus cholera toxin (CT) induced mucosal antibodies as well as systemic antibodies including neutralizing Abs and provided complete protection against infection with pandemic influenza virus A/CA/04/09 (H1N1) in mice. Indeed, the protection efficacy was comparable with that induced by intramuscular (i.m.) immunization route utilized as general administration route of influenza vaccine. These results suggest that s.l. vaccination with the recombinant non-glycosylated HA1 protein offers an alternative strategy to control influenza outbreaks including pandemics.

Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.

BACKGROUND: The ectodomain of matrix protein 2 (M2e) of influenza A virus is a rationale target antigen candidate for the development of a universal vaccine against influenza as M2e undergoes little sequence variation amongst human influenza A strains. Vaccine-induced M2e-specific antibodies (Abs) have been shown to display significant cross-protective activity in animal models. M2e-based vaccine constructs have been shown to be more protective when administered by the intranasal (i.n.) route than after parenteral injection. However, i.n. administration of vaccines poses rare but serious safety issues associated with retrograde passage of inhaled antigens and adjuvants through the olfactory epithelium. In this study, we examined whether the sublingual (s.l.) route could serve as a safe and effective alternative mucosal delivery route for administering a prototype M2e-based vaccine. The mechanism whereby s.l. immunization with M2e vaccine candidate induces broad protection against infection with different influenza virus subtypes was explored. METHODS AND RESULTS: A recombinant M2 protein with three tandem copies of the M2e (3M2eC) was expressed in Escherichia coli. Parenteral immunizations of mice with 3M2eC induced high levels of M2e-specific serum Abs but failed to provide complete protection against lethal challenge with influenza virus. In contrast, s.l. immunization with 3M2eC was superior for inducing protection in mice. In the latter animals, protection was associated with specific Ab responses in the lungs. CONCLUSIONS: The results demonstrate that s.l. immunization with 3M2eC vaccine induced airway mucosal immune responses along with broad cross-protective immunity to influenza. These findings may contribute to the understanding of the M2-based vaccine approach to control epidemic and pandemic influenza infections.